Is the Biotech Bull Market Over?
Akcea Therapeutics and Ionis Pharmaceuticals Snag FDA Approval for Tegsedi
With Hemlibra, Roche seeks to break into tight hemophilia circle
10 biotechs set to shake up the industry's top ranks
Alnylam Indicates Phase III Trial Is Successful Thus Far
FDA Approves Eight Novel Drugs in August
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals' Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops. Alnylam…and RNAi itself…didn’t look like such a good bet four years ago as … Συνεχίστε να διαβάζετε RNAi: The Monoclonal Antibody of the 2020s?.
14 years after floating on Nasdaq, and with a strategic rebranding as well as $2.4bn of accumulated losses under its belt, Alnylam on Friday achieved its proudest milestone yet: its first ever US approval. Patisiran is now the world’s first RNAi drug. So far so bullish. But history suggests that the group’s honeymoon might be … Συνεχίστε να διαβάζετε After Alnylam’s solo maiden launch, here comes the tricky bit.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four or five years ago that early work in immuno-oncology was going to have a huge effect, and it did, when in 2017 the U.S. Food and Drug … Συνεχίστε να διαβάζετε Taking a Look at Trends in Biotherapeutics.
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic to ever be approved. RNAi was discovered about twenty years ago by researchers Andrew Fire and Craig Mello, who received the Nobel Prize for their discovery in 2006. The basic premise … Συνεχίστε να διαβάζετε Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic.